IBRX261120C00016000
IBRX Nov 20 2026 16.00 Call
optionOPRA
InactiveOct 9, 2026
0.28USD-20.000%(-0.07)7Vol1,441OI
Loading…
Underlying
Underlying Price
$8.28
Type
Call
Strike
16
Expiration
Nov 20, 2026
DTE
31d
Moneyness
OTM
Intrinsic
$0.00
IBRX 16 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.05 | +0.00% | 2 | 3 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $0.28 | -20.00% | 7 | 1,441 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.52 | -36.59% | 1 | 2,412 |
| Mar 19, 2027 | 150d | $1.66 | -12.63% | 6 | 55 |
| Apr 16, 2027 | 178d | $1.35 | +0.00% | 200 | 250 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.